For Health Care Professionals Outside the US US Residents VOTRIENT Summary of Product Characteristics Safety Information

Renal cell carcinoma (RCC) is the most common type of kidney cancer1,2

Approximately 9 of 10 kidney cancers are RCC2
20% to 30% have advanced metastatic disease at INITIAL DIAGNOSIS1

VOTRIENT—A therapy designed to fight advanced or metastatic renal cell carcinoma at the source from the start3-5*

See prolonged progression-free survival    

See head-to-head first-line data in advanced RCC    

*The mechanism of action is based on in vivo and in vitro studies.

References: 1. Petejov N, Martinek A. Renal cell carcinoma: review of etiology, pathophysiology and risk factors. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016;160(2):183-194. 2. Eble JN, Sauter G, Epstein JI, Sesterhenn IA, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC Press; 2004. 3. VOTRIENT [summary of product characteristics]. Camberley, UK: Novartis Europharm Limited; February 2018. 4. Hamberg P, Verweij J, Sleijfer S. (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor. Oncologist. 2010;15(6):539-547. 5. Prager GW, Poettler M, Unseld M, Zielinski CC. Angiogenesis in cancer: anti-VEGF escape mechanisms. Transl Lung Cancer Res. 2012;1(1):14-25.
Privacy Site Map Contact Us Summary of Product Characteristics Safety Information

Disclaimer: This is an international website for VOTRIENT® (pazopanib) and is intended for health care professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.

© 2018 Novartis AG | Use of this website is subject to our Terms of Use